Intellectual Property (IP) in Biotechnology: From Trade Secret to Value for Investors and Regulators
In biotech, the term “intellectual property” often brings to mind legal files and filing codes. In reality, IP is a way to give economic form to a discovery without losing its substance. It is the architecture that allows science, processes and the market to communicate. When well designed, IP becomes leverage: it accelerates decisions, clarifies rights and boundaries, makes collaborations negotiable, guides financial flows and helps move from laboratory to factory without dissipating competitive advantage. When improvised, everything becomes unstable: innovation stalls in a conflict over rights, a strategic partner withdraws, a bank asks for guarantees you cannot provide, or a regulator requires rewrites that cost years.
What we really mean by IP
By intellectual property, we mean the set of rights that protect technical solutions, distinctive signs, creative works and confidential information. In biotech, the subject matter is tangible: a molecule, a biopharmaceutical, a device, a formulation, a purification method, an algorithm that guides a clinical decision, a dataset built with effort and quality. Some elements are patent and live in the open; others protect confidentially and work because they remain invisible to competitors. This choice is not a legal indulgence: it is industrial strategy. Some processes, once put into production, can easily be “taken apart” by third parties; in those cases, a patent makes sense because it creates an enforceable right. Other advantages, by contrast, lie in operating windows and in process details that cannot be reconstructed by observing the finished product alone; here the trade secret is often the best route, provided that secrecy is genuine and not merely a statement of intent.
Software and algorithms deserve a separate note. In Europe, unless well-demonstrated technical effects are present, algorithms “as such” are not patented. Protection may arise through copyright, from trade secret, by contracts governing access and use and, when software produces regulated effects (for example, clinical decision support), by a technical documentation that makes its lifecycle controllable. In the United States the scope is more flexible, but remains highly case-specific. Here too, the strategy cannot be reduced to a patent “yes/no”: it must be designed with those who write the algorithm and those who will have to defend it legally.
Inventors, rights and governance: bringing order before moving fast
A common mistake is to confuse theinventor with the proprietary. The first is the natural person who made a creative contribution; the second is the entity (company, organisation) that holds the rights by virtue of contracts or internal regulations. In joint projects, what each party brings at the outset must be distinguished from (Background IP) from what is created together (Foreground IP). This is where future peace of mind is decided: who will be able to use what, in which fields of application, in which territories, and with what revenue-sharing arrangement. Governance written too late often becomes an endless negotiation and risks creating a blockage precisely when results begin to emerge.
The timing is another crucial variable. Novelty is the first requirement for a patent, and it can be lost through disclosure, even accidental: a poster, a public demo or a YouTube pitch can destroy protection. Coordinating scientific communication, PR and legal is a duty; filing before speaking is a rule that can save years of work.
Explore the topics
Freedom To Operate: having a right is not enough
Many people confuse patentability with freedom to operate. Having a patent does not automatically mean being able to operate without risk in target countries. The Freedom To Operate (FTO) is the analysis that assesses the risk of infringing third-party rights in the markets where you intend to sell or manufacture. It is an uncomfortable but necessary exercise: it can suggest technical changes that free you from constraints, guide cross-licensing agreements, and even change the list of countries where it makes sense to operate. Ignoring FTO exposes you to injunctions, delays and damages claims: costs that far exceed those of a sound study carried out in advance.
IP that drives processes rather than chasing them
Intellectual property must not live in a separate office. It must influence CMC (Chemistry, Manufacturing and Controls) and develop in dialogue with those who design the process, qualify suppliers and set specifications. Sometimes a “process secret” is your real competitive advantage; the question then becomes: can suppliers reconstruct it from the technical requirements? the change control will expose it to the world when you change plant or raw material? do internal procedures genuinely protect access to critical information? At other times, the right route is a patent with well-written claims and a dossier linking technical choice, yield, purity, stability. In both cases, the direction is the same: IP does not merely “cover” what already exists, but guides what you put into production.
Contracts that give substance to protection
A range of contractual instruments orbit around IP, and they are not formalities. Agreements for confidentiality protect preliminary exchanges but are not sufficient, because they do not turn into assets what is not governed elsewhere. The MTA govern transfers of biological materials and define limits of use and obligations for return or destruction. The licensing define fields of use, territories, royalties, milestones, sublicensing rights and reversion clauses if the partner fails to meet objectives. Agreements for sponsored or joint research establish how publications and pre-publication reviews are managed and, above all, how the Foreground IP. Finally, if personal or clinical data are being processed, the privacy must be designed with the same rigour: legal bases, roles, responsibilities, transfers outside the EU and security measures. A company can lose value because of a flaw in the DPA just as much as because of a poorly drafted patent.
Patent or trade secret? A competitive-positioning choice
There is no universal answer. The logic is this: if a competitor could reach your technical core by observing the product and processes, the patent is your barrier. If your advantage lies in hidden parameters and their internal protection is strong, secrecy is powerful and does not expire after twenty years. Hybrid routes are also possible: patents covering the visible perimeter and internal protocols protecting operational refinements. For the choice to be serious, it must be weighed against the market strategy: who the competitors are, what reverse-engineering capabilities they have, and how quickly they could react.
Value enhancement: how IP translates into numbers
Intellectual property is “value” when it holds up in three contexts. The first is tax-related, with frameworks such as the Patent Box that reward income attributable to IP: it is not a gift, but a discipline that forces you to demonstrate how innovation generates margin and how R&D costs translate into stable performance. The second is the subsidised finance: funding calls and instruments such as Smart&Start make sense if they fit into your technical and regulatory roadmap, not if they distort it. The third is the corporate financing: when you need to finance plants, cleanrooms, validations and supply chains, IP protects the investment by reducing the risk of copying and strengthening commercial agreements. In all three cases, IP is not a label: it is the verifiable narrative that links technical choices, quality outcomes and economic returns.
Territory and duration: choosing where to make an impact
Intellectual-property rights have geographies and timelines. A patent is effective where it is filed and generally lasts twenty years from the filing date, subject to exceptions and supplementary protection certificates in the pharmaceutical field that may extend protection. Trade marks can last for a long time if renewed. Trade secrets last for as long as they remain secret and protected. Countries are not selected by preference: the map is built on the production strategy, on the markets with realistic revenue potential, on the jurisdictions where enforcement is economically viable, not merely theoretical. Protecting everywhere is pointless; protecting in the wrong place is expensive; protecting well where it matters makes the difference when scale-up begins.
Data, datasets and AI: the new frontier of protection
Data have become the new strategic material. A clinical dataset collected to high standards, an environmental registry with a rigorous chain of custody, and a pipeline that turns raw signal into clinically interpretable features are asset. Protection works on several fronts: access and use agreements, clear licences, quality controls, traceability of transformations, and technical and organisational measures to prevent abusive extraction. The algorithm built on those data, when it guides clinical or industrial decisions, must be explainable and verifiable: it is an indirect but extremely powerful form of protection, because it makes the system acceptable for regulators, partners and customers. Protection and acceptability overlap here: without one, the other never materialises.
A methodological rule: IP as design, not as a patch
If IP enters after the project is completed, it is usually too late. Protection becomes a patch, and technical choices are difficult to defend. If, instead, IP is co-design, guides CMC and quality, informs contracts with partners and suppliers, suggests the timing of public communications, supports reporting for Patent Box and funding calls, and makes dialogue with investors and banks more transparent. With this approach, due diligence is not a maturity test you fear: it is the daily mirror used to check that the technical and legal narratives tell the the same thing.
What does “being ready” mean when entering production?
Being ready is not the same as having a patent-application number. Being ready means that the processes are stable and traceable, that the suppliers do not erode your trade secret without you noticing, that the documentation stands up to an audit with confidence, that the staff knows not only what to do but why, that the data are intact and retrievable. It also means that the IP scope is clear enough to be guaranteed into a financial contract, with known boundaries and risks. At that point, intellectual property stops being a cost and becomes a multiplier: gives you access to better credit lines, more serious partnerships and smoother regulatory timelines.
How we work on IP in the Technoscience ecosystem
When we join a project, we do not immediately ask “where is the patent?”. We ask what you are actually protecting, how you are protecting it, who may access it and under what conditions, how it connects to the process and data, what happens if a supplier changes or if you move to a new plant. These answers lead to a map: required filings and filing timelines, elements to keep secret, contracts to draft or revise, steps requiring FTO, sensible territories, alignment with incentives and scale-up plans. The objective is not to fill a drawer with documents; it is to create a coherent narrative that withstands day-to-day practice and unexpected events.
How to enter the Technoscience ecosystem (without losing months)
The first step is a biotech IP fit check of a few pages: technology you want to protect or monetise, status of experimental data, known prior art, agreements already signed (NDA, CDA, collaboration), target markets and timelines. In a short call, we align expectations and build an initial intellectual-property map: what is genuinely patentable, what should be kept as a trade secret, which rights belong to whom, which gaps need to be closed in order to engage with investors and regulators without disclosing too much or too little.
If the framework is sound, we propose a biotech IP strategy concrete: filing pathway (provisional, PCT, extensions), alignment with TRL and data, ownership and licensing rules, consistency with funding calls, Patent Box and investor due diligence. If serious issues emerge (hostile prior art, pre-existing rights, weak data), we make them explicit and—where possible—indicate how to strengthen the position before spending on patents or negotiations that would not withstand scrutiny.
Choose Technoscience!
If you are working on a biotech technology and want to understand how to turn intellectual property from a “well-kept secret” into an asset that convinces investors and regulators, use this form to request an IP fit check. In a short call, we analyse: development status (TRL), available results, known prior art, existing agreements and objectives (patenting, licensing, negotiating with partners or investors, accessing incentives such as the Patent Box). If the foundation is solid, we design a biotech IP roadmap together: choices between patent and trade secret, filing timelines, management of co-ownership and licensing, alignment with regulatory requirements and future due diligence. If key elements are missing, we say so immediately: it is better to strengthen the data, documentation and strategy before committing budget, equity or rights that you will not be able to recover.
Frequently Asked Questions
The questions you ask us most often
In the biotech the development cycle is long, costly and regulated: without a strategy for intellectual property (IP) clear, it is difficult to convince investors, industrial partners and regulators that the project will generate defensible value. Strong IP makes it possible to protect molecules, processes, platforms or algorithms, structure licensing and co-development agreements, and access instruments such as Patent Box and subsidised finance. In practice, IP is the legal translation of years of R&D into a negotiable asset.
There is no single answer: in many cases, an effective biotech IP strategy combines patent and trade secret. A patent makes sense when a strong, publicly recognised right is needed to engage with investors, partners and regulators; a trade secret is preferable when the know-how is difficult to reverse engineer or when disclosure through a patent would expose too much of the technology. The choice depends on TRL, the competitive landscape, the mode of industrial exploitation and the risks of know-how leakage.
For a biotech patent with a good chance of withstanding examination and due diligence, at minimum you need: robust experimental data (not merely a concept), a clear distinction from the prior art, a precise definition of the scope of protection (molecule, use, process, kit, platform), traceable documentation of who did what and when, and consistency between patent claims and the development plan (TRL, future studies, regulatory requirements). Without these elements, the risk is paying for a weak right that is difficult to enforce or monetise.
A biotech IP strategy when well constructed, facilitates access to instruments such as Patent Box and other tax incentives linked to intellectual property. This requires clear rights (patents, software, protected know-how), traceability of R&D costs linked to the asset, and technical documentation demonstrating the relationship between innovation, economic outcomes and tax benefit. The typical mistake is to think about Patent Box only downstream: in reality, it is better to design IP and the technical-financial pathway in a coordinated way from the outset.
In due diligence on biotech IP, investors and partners look not only at the number of patents but at the quality of the IP position: strength of claims against prior art, freedom to operate (FTO), clarity of ownership and co-ownership, absence of hidden constraints from legacy agreements, and consistency among IP, TRL and the regulatory plan. Governance also matters: who decides on extensions, licensing and enforcement, and how conflicts of interest among academia, spin-offs and industry are managed. An IP strategy that is easy to explain and well documented carries as much weight as a strong experimental result.